We are facing a global epidemic of obesity and type 2 diabetes. Weight loss, in the context of obesity and type 2 diabetes, may improve glycaemic control and weight-related comorbidities, and in some cases, induce diabetes remission. Although lifestyle-based weight loss strategies may be initially successful, most are not effective long-term. There is an increasing need to consider pharmacological approaches to assist weight loss in diabetes-obesity. Older glucose-lowering agents may cause weight gain, whereas the newer drug classes, sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagonlike peptide receptor agonists (GLP-1 RAs), concomitantly target weight loss and glycaemic control. Clinical trial data suggest that both SGLT2i and GLP1 RAs cause a mean weight loss of approximately 2 to 3 kg but real-world evidence and clinical experience suggests a significant heterogeneity in the magnitude of the weight loss or the magnitude of the actual weight loss is significantly less than anticipated (SGLT2i).
saturated, leading to hepatic and peripheral insulin resistance and progressive β-cell failure, ultimately leading to hyperglycaemia. 4 Weight loss is critically important to prevent such ectopic fat deposition, exemplified by the finding that in the Diabetes Prevention Program, every 1 kg weight loss was associated with a 16% relative risk reduction in individuals progressing from impaired glucose tolerance to T2DM. 5 In T2DM, even moderate weight loss (3%-5%) has significant health benefits, beyond improving glycaemic control, improving other weight-related comorbidities in a dose-dependent manner. 6 This is best mechanistically illustrated by the rapid improvement in glucose homeostasis in patients with T2DM with a low calorie diet. The dramatic and rapid metabolic improvement preceding any significant weight loss is explained by mobilization of liver fat (reducing hepatic glucose output with enhanced hepatic insulin resistance) and mobilization of pancreatic fat (restoring first phase of insulin secretory response). 7 Longer-term results from individuals following bariatric surgery show that this is associated with long-term remission of T2DM, a reduced incidence of microvascular and macrovascular complications and reduced mortality. 8, 9 Currently, however, only a minority will have access to either of these interventions, with other structured interventions difficult to implement in clinical practice.
The typical trajectory of weight change with a lifestyle intervention (eg, diet, exercise, and behaviour change) is characterized by early weight loss, plateauing at around 6 months, followed by an insidious and progressive weight gain over the following months. 10 When clinically appropriate, there is increasing attention towards pharmacological approaches, with reinvigorated efforts to reinforce and implement lifestyle changes, to assist weight loss over the longer term. There has been a disappointing history of effective therapies for weight loss, with a number of agents being withdrawn following their approval, including sibutramine (increased risk of adverse cardiovascular events) and rimonobant (mood disorders and suicidal ideation). Currently, five anti-obesity drugs have been approved by the US Food and Drug Administration (FDA): (1) combination of phentermine and topiramate, (2) 5-hydroxytryptamine2C (5-HT 2C ) serotonin receptor agonist lorcaserin, (3) naltrexone/bupropion, (4) liraglutide 3.0 mg, and (5) orlistat, but only the latter three are available in Europe. Older glucose-lowering therapies (sulfonylureas, thiazolidenediones, and insulin) can exacerbate weight gain 11 but the newer glucose-lowering therapies such as glucagon-like peptide receptor agonists (GLP-1 RAs)
and sodium-glucose co-transporter 2 inhibitors (SGLT2i) can further enhance weight loss, concomitantly lowering HbA1c and body weight.
However, despite contrasting modes of action to reduce body weight, both drug classes are associated with highly variable weight loss and their weight-lowering effect unpredictable (Table 1) .
Weight loss variability between individuals in response to SGLT2i
or GLP-1 RAs is clearly not explained wholly by heterogeneity in the pharmacological response. Ongoing mechanistic studies and further clinical experience of these agents, alone and in combination in different populations, will provide insight into the physiological, psychological, and pharmacogenetic basis for weight loss variability. A better understanding of the mechanisms involved and the possibility to predict treatment outcomes could lead to a change in patient treatment and help optimize outcomes. This review will consider the variability of the specific metabolic and appetitive adaptations that may attenuate weight loss with SGLT2i and provide possible mechanistic insight for weight loss variability with GLP1 RAs. However, we emphasize that the physiological basis for weight loss variability is likely generic across all weight loss interventions, be it achieved through lifestyle, pharmacological, or surgical interventions. 
| With weight gain
In obesity/weight gain, not only is there a homeostatic deficit (reduced satiety or fullness) but this is also potentially coupled with an overactive hedonic/reward system (failure of satiety to impact on hunger responsiveness to food cues), with a resulting preference for energydense food and potentially greater influence from environmental factors. 34 For example, if you have ever eaten a piece of chocolate cake, even though you might feel completely "full," your reward system overrides the homeostatic system, encouraging you to eat the cake. weight have lower rates of fat oxidation with those successful at maintaining weight loss long-term (responders) having higher oxidation rates than those experiencing weight regain (non-responders).
47-49
During periods of negative energy balance and reduced energy stores (weight loss), attempts are made to maintain homeostasis through hormonal signalling (eg, leptin and insulin) and other afferent neuronal signals relaying information to the brain (hypothalamus) to stimulate appetite and promote weight gain. An important finding is that many of these hormonal alterations persist for 12 months or more after weight loss, even after weight regain. 50 Coupled with a potentially heightened hedonic drive for consumption of highly palatable energy-dense food, this may completely overwhelm the homeostatic system driving further food intake even when there is no metabolic need, hampering long-term weight loss. Measuring eating behaviour and appetite can be challenging and inaccurate. Energy intake in the DIRECT study, comparing low fat versus low carbohydrate diets, was incorrectly believed to be unchanged based on a 24-hour recall and questionnaires leading to the assumption that bodyweight plateau and weight regain was a result of change in energy expenditure only. 51 Using a validated mathematical modelling to determine energy intake, it can be clearly seen that the reductions in energy intake progressively subside, 52 either through lack of compliance, or compensatory changes in appetite.
Taken together, to accurately predict weight loss with any lifestyle or pharmacological intervention imposing an energy deficit, one must factor in initial body weight and body composition, differential mobilization of fat versus lean tissue with progressive weight change leading to dynamic changes in resting metabolic rate and substrate oxidation, and compensatory changes in appetite that may occur.
| RESPONDERS VERSUS NONRESPONDERS
The concept of "responders" and "non-responders" applies to any physiological outcome with any intervention, eg, change in HbA1c with glucose-lowering therapies, or changes in V0 2 max with exercise training. Clinical trial data reporting mean weight loss as an outcome measure conceal the heterogeneity of weight change, with significant vs. absent/negligible weight loss giving rise to responder (defined as greater than or equal to 5% weight loss) vs. non-responder populations (defined as less than or equal to 5% weight loss). However, it should be recognized that the response is not dichotomous and usually follows a normal distribution curve that is shifted to the left or right depending on the intervention ( Figure 2 ). All recently approved weight loss medication labels apply "stopping rules" based on responder analyses, stipulating thresholds when pharmacotherapy should be discontinued if clinically relevant weight loss has not occurred (based on risk/benefit and cost). Several studies have attempted to explain the heterogeneity in weight change by stratification of weight loss: responders (greater than or equal to 5%
weight loss) and non-responders (less than or equal to 5% body weight loss). 53, 54 Others have identified three levels of response: responders (more than 5% weight loss), non-responders (less than 5% weight loss),
and those who gained weight. 55 In such cases, additional phenotype (eg, early weight loss), psychological and physiological adaptations, were discussed but no firm conclusions were drawn.
Obesity represents a chronic disease, and the critical consideration during a weight loss intervention is not only the shortmedium-term weight loss (3-6 months) but also longer-term maintenance of weight loss (1-2 years or more). After weight loss, rates of recidivism are universally high with many suggesting that there are compensatory mechanisms involved to defend a weight "set-point" and resist weight loss. Should physicians discontinue drug therapy in apparent non-responders, minimizing side effects from ineffective treatment and rationalizing scarce health resources more stringently, or is this an opportunity to intensify treatment? There is little consensus on how to treat patients who reached the initial milestones but later plateau or indeed gain weight. Further research is required to optimize long-term weight loss strategies, particularly in individuals with T2DM.
| TREATMENT VARIABILITY
A complex interplay of non-biological and biological factors may explain treatment variability ( Figure 3 ).
The differential ways in which an, "obesogenic environment" may influence obesity-promoting behaviour (eg, eat more, do less) among individuals is not fully understood. 56 An almost overwhelming number of non-biological factors in our circumstances and environment combine together to determine our health. Determinants of weight may include the social and economic environment (eg, income, education, and employment), the physical environment (eg, food availability and safe areas for physical activity), and access to healthcare. Could it be that "non-response" in some people is simply because of the obesogenic environment counteracting any therapeutic attempt of weight loss? Some individuals may be better than others at resisting such an environment. Implementation of policies that prioritize healthy food environments and systems is beyond the scope of this review but warrants significant consideration.
Compliance with the prescribed medication or the concomitant prescribing of multiple glucose-lowering agents, which counteract the desired weight loss should also be considered. [61] [62] [63] [64] Despite this, patients with apparently similar phenotypes do not always achieve the same weight change.
| GLP-1 RECEPTOR AGONISTS
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from the L-cells in the small intestine, increasing pancreatic β-cells' insulin secretion (in a glucose dependent manner) and inhibiting hepatic glucose production via reduced α-cell glucagon secretion. 65, 66 GLP-1 is a physiological regulator of appetite and food intake via the central GLP-1 receptors, mediating reduced appetite and weight loss.
67,68
Administration of GLP-1 to rats into key mesolimbic structures (ventral segmental area and nucleus accumbens) resulted in decreased motivated behaviour for sucrose in rats, eg, reduction in how hard the rat was willing to work for a sweet reward. 69 Conversely, blocking the GLP-1 receptor increases food intake in satiated rats. 
| Effect of gender and baseline weight
In the liraglutide 3.0 mg clinical development programme, weight loss and glycaemia improvement were dose-dependent with higher doses required for maximum weight reduction. 20, 72 There was a tendency for greater weight loss in females versus males, and less weight loss in subjects with a BMI > 40 kg m 2 .
| Pharmacokinetic factors
Limited head-to-head studies of GLP- to food cues in subjects with obesity, with and without T2DM, correlating with reductions in food intake. 
| SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS (SGLT2I)
It is widely accepted that the sodium-dependent glucose 
| Possible adaptations to SGLT2i therapy that limit weight loss
There is great interest as to why SGLT2i therapy is not associated with more pronounced weight loss considering the caloric loss/energy deficit (300 kcal day
; approximately 1,300 kJ) accompanying the enhanced glucose excretion (75 g of daily urinary glucose excretion). 97 As an energy deficit of 15 MJ week −1 would be expected to be associated with a 0.5 kg loss of body weight per week (using the "static weight loss rule"), the expected weight loss over 24 weeks treatment with SGLT2i would be approximately 7 kg (assuming no compensatory changes in energy balance or diuresis).
| Compensatory hyperphagia
It has been speculated that the discrepancy between observed and expected weight loss with SGLT2i may arise because of compensatory increases in energy intake and changes in energy expenditure that act to attenuate the energy imbalance. In rodent models, SGLT2 deletion or chronic treatment with the SGLT2i dapagliflozin resulted in a compensatory increase in caloric intake. 104, 105 Rats with dietary obesity lose weight when treated with dapagliflozin (approximately 4%), but this is associated with a 30% increase in energy intake. Furthermore, weight loss was four times larger when animals were pair-fed as compared with ad-libitum diet. 105 Studies using alternative SGLT2i in animals have not demonstrated the same increase in energy intake (approximately 4%). 106, 107 Mathematical models based on studies of SGLT2i in patients with T2DM predict that energy intake after weight loss because of urinary glucose excretion (UGE) may exceed adaptions in energy expenditure, contributing to difficulties with sustained weight loss. 108, 109 In one study, weight loss was less than a third of that predicted by the model, with the majority of the difference accounted for by an increase in energy intake (13%), with a small contribution for diet-induced thermogenesis. 108 Considering the hormonal and metabolic adaptations that occur with weight loss (from any intervention) that tries to limit weight gain and restore body weight back to its previous "set point," the compensatory hyperphagia reported with SGLT2i therapy is in many ways entirely appropriate.
| Changes in energy expenditure/substrate utilization
There are a paucity of human interventional data on whole body metabolic changes occurring secondary to increased urinary glucose excretion with SGLT2i. Several publications have shown that the increased urinary glucose excretion following SGLT2 inhibition is associated with a paradoxical increase in endogenous (hepatic) glucose production [108] [109] [110] possibly caused by a compensatory release of glucagon from the α-cells in the pancreatic islets. 111 This will partially negate the SGLT2i effect on glucose concentration, but would not necessarily modify weight loss.
In SGLT2 knockout, mice food intake was greater, physical activity increased, energy expenditure was higher, and respiratory quotient fell, consistent with a shift from carbohydrate to fat metabolism. 105 Human studies have demonstrated that chronic (4 weeks) administration of empagliflozin causes a shift in fuel utilization from carbohydrate towards fatty substrates to cause loss of fat mass and weight loss, but no changes were seen in resting or postprandial energy expenditure as measured by indirect calorimetry, implying that energy intake is increased to explain the discrepancies in weight loss seen. 108 The development of euglycaemic ketoacidosis in T2DM subjects treated with SGLT2i has been reported. While the underlying mechanism is poorly understood, it is suggestive of complex metabolic adaptations taking place. Changes in substrate utilization from glucose to lipid provides an explanation for increased ketone production with SGLT2i. 
| Genetic polymorphisms
A large number of genetic polymorphisms have been described affecting the response to treatment with other oral hypoglycaemic agents.
This may explain the inter-individual response to SGLT2i and there is an emergence of data regarding genetic variability. In a population pharmacokinetic model of canagliflozin in diabetic and non-diabetic individuals, Hoeben at al reported UGT1A9*3 among several other covariates to influence the drug's elimination rate. 112 Carriers of reduced function variants UGT1A9*3 had increased plasma concentrations of canagliflozin, although the clinical significance of this is presumably small. Nonsense and missense mutations in the SCL5A2 gene coding for the glucose transporter SGLT2 cause familial renal glycosuria, characterized by urinary glucose excretion in the presence of low-normal glucose levels. 113 Interestingly, these individuals appear to have normal growth and are asymptomatic. 114 The presence of normal blood glucose concentrations, despite significant glycosuria, highlights that potentially counter-regulatory mechanisms are being activated to compensate for the urinary loss.
| COMBINATION THERAPY WITH SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS (SGLT2I)
As discussed previously, the anticipated weight loss with SGLT2i is less than expected, possibly explained by a compensatory increase in food intake. It therefore seems logical to combine SGLT2i with anorexigenic drugs.
With phentermine
Results of a phase II trial of the combination of phentermine 15 mg 
